selenoo1 Antibody

What is Selenoprotein P and why are antibodies against it significant?

Selenoprotein P (SeP) is a selenium-rich extracellular protein that functions as the major selenium transport protein in plasma. It constitutes approximately 53% of total plasma selenium in humans . Beyond its role in selenium transport, SeP has been identified as a hepatokine that promotes insulin resistance in type 2 diabetes, linking it to metabolic disorders . Antibodies against SeP are significant because they can neutralize its activity, potentially interrupting its pathological effects in metabolic diseases. These antibodies serve dual purposes: as research tools to understand SeP biology and as potential therapeutic agents for treating conditions where SeP dysregulation occurs. The development of specific anti-SeP antibodies has enabled researchers to quantify SeP levels in biological samples and investigate its physiological and pathological functions in various tissues and disease states .

How are monoclonal antibodies against Selenoprotein P produced?

The production of monoclonal antibodies against human Selenoprotein P follows a systematic immunization and hybridoma development process. Researchers begin by purifying human Selenoprotein P from plasma. The purified protein is then used to immunize laboratory animals, typically rats . Following immunization, B cells are isolated from the animals' spleens and fused with myeloma cells to create hybridomas. These hybridomas are cloned and screened for specific antibody production against SeP using techniques such as ELISA and Western blotting.

The process involves several critical steps:

• Purification of native human Selenoprotein P from plasma

• Immunization of rats with purified SeP

• Hybridization of B cells with myeloma cells

• Cloning and selection of hybridoma cells

• Screening for specific antibodies using immunoassays

• Expansion of positive clones for antibody production

This methodology has successfully yielded multiple monoclonal antibodies with different epitope specificities. For instance, researchers have established eleven hybridomas producing specific antibodies against human selenoprotein P . These antibodies can be further characterized based on their binding properties, neutralizing capacity, and recognition of specific domains within the SeP protein structure.

What methods are used to confirm the specificity of anti-Selenoprotein P antibodies?

Confirming the specificity of anti-Selenoprotein P antibodies requires multiple complementary approaches to ensure reliable research outcomes. Several methodological strategies are employed:

• Immunoprecipitation and Western blotting: Anti-SeP antibodies should specifically recognize and pull down SeP from complex biological samples like plasma. Western blot analysis of immunoprecipitates should reveal a single band at the expected molecular weight of SeP (approximately 69 kDa for human SeP) . This confirms that the antibody binds specifically to the target protein.

• Competitive binding assays: Researchers can perform competitive binding experiments where unlabeled purified SeP competes with labeled SeP for antibody binding. A dose-dependent reduction in antibody binding in the presence of excess unlabeled SeP confirms specificity.

• Cross-reactivity testing: Antibodies should be tested against related selenoproteins and other plasma proteins to ensure they don't cross-react with non-target proteins.

• Cell surface binding inhibition: For antibodies targeting cell-binding domains of SeP, researchers can conduct cell surface binding inhibition assays. For example, studies have shown that certain anti-SeP monoclonal antibodies (like AE2 and BD1) significantly inhibit the binding of human SeP to C2C12 cells .

• Functional neutralization assays: Antibodies with neutralizing activity can be validated by testing their ability to block SeP function. For instance, researchers have demonstrated that anti-SeP antibodies can inhibit SeP-mediated selenium supply to cells, as measured by reduced expression of cellular selenoproteins like GPx1 and TrxR1 .

This multi-faceted approach ensures that antibodies used in research are truly specific to SeP and suitable for their intended applications.

How can researchers quantify Selenoprotein P using antibody-based techniques?

Researchers can quantify Selenoprotein P in biological samples using several antibody-based techniques, with enzyme-linked immunosorbent assay (ELISA) being the most common and reliable method. A sandwich ELISA utilizing two different monoclonal antibodies recognizing distinct epitopes on SeP provides sensitive and specific quantification .

The methodological procedure involves:

• Sandwich ELISA development:

  • Coating plates with a capture anti-SeP monoclonal antibody

  • Adding samples containing SeP

  • Detecting bound SeP with a different labeled anti-SeP monoclonal antibody

  • Quantifying signal intensity relative to a standard curve of purified SeP

• Sample preparation considerations:

  • Plasma samples typically require dilution to fall within the linear range of the assay

  • Tissue homogenates may need specialized extraction protocols to release SeP

  • Potential interfering substances should be identified and controlled for

• Validation parameters:

  • Establishing assay sensitivity (lower limit of detection typically in ng/ml range)

  • Determining intra- and inter-assay coefficients of variation

  • Confirming linearity across the relevant concentration range

  • Demonstrating recovery of known quantities of SeP added to samples

Using this approach, researchers have established that the normal concentration of SeP in human plasma is approximately 5.3 ± 1.1 μg/ml . This quantification method enables studies of SeP levels in various physiological and pathological conditions, such as monitoring changes during interventions like LDL-apheresis, which has been shown to decrease plasma SeP concentration from 5.7 to 2.3 μg/ml .

How do neutralizing antibodies against Selenoprotein P affect glucose metabolism in diabetes models?

Neutralizing antibodies against Selenoprotein P demonstrate significant beneficial effects on glucose metabolism in diabetes models through multiple mechanisms. The administration of SeP-neutralizing antibodies addresses the pathological effects of elevated SeP levels, which are characteristic of type 2 diabetes.

Mechanistically, neutralizing antibodies against SeP improve glucose metabolism through:

• Enhanced insulin secretion: Administration of SeP-neutralizing antibodies improves insulin secretion from pancreatic β-cells. Studies using MIN6 cells (a pancreatic β-cell model) showed that excess SeP treatment decreased cellular insulin levels and reduced glucose-stimulated insulin secretion. Anti-SeP antibodies reversed these effects, restoring normal insulin production and secretion capacity .

• Improved insulin sensitivity: SeP promotes insulin resistance in peripheral tissues. Neutralizing antibodies counteract this effect, enhancing glucose uptake in response to insulin in target tissues.

• Prevention of Se oversupply: Excess selenium supply via SeP appears to be detrimental to pancreatic β-cell function. Neutralizing antibodies block this activity, as evidenced by their ability to inhibit the cellular uptake of SeP and the subsequent increase in cellular selenoproteins like GPx1 .

In mouse models of type 2 diabetes, administration of antibodies targeting the first histidine-rich region (FHR) of SeP significantly improved glucose intolerance and insulin secretion . The table below summarizes key experimental findings from diabetes model studies:

These findings establish a direct link between SeP neutralization and metabolic improvements, suggesting that targeting SeP with neutralizing antibodies represents a novel therapeutic strategy for type 2 diabetes.

What epitopes on Selenoprotein P are targeted by neutralizing antibodies and why is this significant?

The epitope specificity of anti-Selenoprotein P antibodies is critical for their neutralizing capacity and therapeutic potential. Research has identified specific domains within the SeP protein structure that, when targeted by antibodies, effectively neutralize SeP's pathological activities while potentially preserving its physiological functions.

Epitope mapping has revealed several key insights:

• First Histidine-Rich Region (FHR) targeting: The monoclonal antibody AE2 recognizes a region of human SeP adjacent to the first histidine-rich region . This region appears critical for SeP's pathological effects on glucose metabolism. Antibodies targeting this domain demonstrate significant neutralizing activity.

• Functional domain specificity: Different domains of SeP mediate distinct functions:

  • The N-terminal domain contains the selenocysteine-rich region with enzymatic activity

  • The C-terminal domain is involved in selenium transport

  • The histidine-rich regions may mediate cell surface binding

• Species cross-reactivity considerations: Some antibodies are specific to human SeP, while others may cross-react with mouse SeP. For translational research, understanding these species differences is crucial. Studies have shown that polyclonal antibodies against mouse SeP FHR improve glucose intolerance and insulin secretion in mouse models of diabetes .

• Structural implications: The binding of antibodies to specific epitopes may induce conformational changes in SeP that inhibit its interaction with cellular receptors like LRP1, which functions as an SeP receptor in certain cell types .

The significance of epitope targeting lies in the potential for selective inhibition of SeP functions. By targeting specific domains, researchers can develop antibodies that block pathological activities (like promoting insulin resistance) while potentially preserving beneficial functions (like physiological selenium transport). This selective inhibition approach could lead to more refined therapeutic strategies with fewer side effects compared to complete SeP suppression.

How can researchers assess the selenium-supply inhibition activity of anti-Selenoprotein P antibodies?

Assessing the selenium-supply inhibition activity of anti-Selenoprotein P antibodies requires sophisticated cellular assays that measure the impact on selenoprotein biosynthesis. Since SeP functions as a selenium transport protein, effective neutralizing antibodies should inhibit its ability to deliver selenium to target cells.

A comprehensive assessment methodology includes:

• Cellular selenoprotein expression analysis:

  • Culture cells (such as differentiated C2C12 myocytes) with SeP in the presence or absence of test antibodies

  • Measure cellular selenoprotein levels (particularly GPx1 and TrxR1) by Western blotting

  • Quantify band intensity to determine the degree of inhibition

• Dose-response relationships:

  • Test increasing concentrations of antibodies against a fixed concentration of SeP

  • Calculate IC50 values for selenium-supply inhibition

  • Compare potency of different antibody clones or formats

• Cellular selenium uptake measurements:

  • Use radioactive selenium (75Se) to track SeP-mediated selenium delivery

  • Measure intracellular accumulation of 75Se in the presence and absence of neutralizing antibodies

  • Calculate percent inhibition of selenium uptake

• Functional consequences assessment:

  • Examine downstream effects of selenoprotein reduction

  • For pancreatic β-cells (MIN6 cells), measure insulin content and glucose-stimulated insulin secretion

  • In muscle cells, assess insulin signaling pathway components

An example experimental protocol derived from published research involves incubating differentiated C2C12 myocytes with varying concentrations of human SeP (hSeP) and sodium selenite with or without anti-SeP antibodies. The levels of cellular selenoproteins GPx1 and TrxR1 serve as indicators of selenium supply activity. Researchers have observed that these selenoprotein levels increase in an hSeP- and sodium selenite-concentration-dependent manner, providing a reliable readout for antibody-mediated inhibition .

This methodological approach enables researchers to quantitatively evaluate the neutralizing potency of different antibodies and select optimal candidates for further development as research tools or therapeutic agents.

What techniques are used to investigate the in vivo efficacy of Selenoprotein P antibodies?

Investigating the in vivo efficacy of Selenoprotein P antibodies requires comprehensive animal studies with multiple assessment parameters. These techniques enable researchers to translate in vitro findings to physiologically relevant contexts and evaluate therapeutic potential.

The methodological approach encompasses:

• Animal model selection:

  • Diet-induced obesity/diabetes models (high-fat diet)

  • Genetic models of type 2 diabetes (db/db or ob/ob mice)

  • Animals with human SeP administration to induce metabolic dysfunction

• Antibody administration protocols:

  • Determination of optimal dosing (typically 1-10 mg/kg)

  • Route of administration (intraperitoneal or intravenous)

  • Treatment schedule (single dose vs. repeated administration)

  • Control groups (isotype control antibodies)

• Glucose metabolism assessment:

  • Oral glucose tolerance tests (OGTT)

  • Insulin tolerance tests (ITT)

  • Measurement of fasting and postprandial blood glucose and insulin levels

  • Hyperinsulinemic-euglycemic clamp studies for insulin sensitivity

• Tissue-specific analyses:

  • Pancreatic insulin content measurement

  • Islet isolation and ex vivo glucose-stimulated insulin secretion

  • Muscle and liver insulin signaling assessment (phosphorylation of insulin receptor, IRS, Akt)

  • Immunohistochemical analysis of tissues for antibody distribution

• Alternative gene delivery approaches:

  • For long-term antibody expression, recombinant adeno-associated virus (rAAV) vectors can be used

  • Intramuscular injection of rAAV vectors encoding antibody genes results in sustained antibody production by muscle cells

  • Blood samples can be collected to monitor antibody levels over time

Research has demonstrated that administration of anti-human SeP monoclonal antibody AE2 to mice significantly improves glucose intolerance and insulin resistance induced by human SeP administration . Similarly, a polyclonal antibody against the mouse SeP first histidine-rich region improved glucose intolerance and insulin secretion in a mouse model of diabetes . These findings validate the in vivo efficacy of SeP-neutralizing antibodies and support their continued development as potential therapeutic agents.

How can researchers develop bispecific or multi-specific antibodies targeting Selenoprotein P and related metabolic pathways?

Developing bispecific or multi-specific antibodies that simultaneously target Selenoprotein P and related metabolic pathway components represents an advanced approach to enhance therapeutic efficacy. This strategy aims to address multiple pathological mechanisms underlying metabolic disorders through a single molecular entity.

The methodological framework for developing such advanced antibodies includes:

• Target selection and validation:

  • Identify complementary targets in metabolic pathways (e.g., SeP plus insulin receptor, glucagon receptor, or inflammatory mediators)

  • Validate targets using knockout models or existing monoclonal antibodies

  • Confirm synergistic effects of dual targeting through combination studies

• Antibody engineering approaches:

  • Fragment-based methods: using scFv (single-chain variable fragments) from different antibodies

  • IgG-like formats: creating asymmetric antibodies with different binding specificities

  • Alternative scaffold fusion: combining anti-SeP binding domains with other protein scaffolds

• Production and purification strategies:

  • Mammalian expression systems (CHO, HEK293) for proper glycosylation

  • Optimization of heavy-to-light chain ratios for bispecific formats

  • Specialized purification protocols to separate desired bispecific molecules

• Functional characterization:

  • Binding kinetics to each target (Surface Plasmon Resonance)

  • Simultaneous binding demonstration (sandwich ELISAs)

  • Cell-based activity assays for each targeted pathway

  • Synergistic activity assessment in complex biological systems

• In vivo testing considerations:

  • Pharmacokinetic studies to determine half-life and tissue distribution

  • Dose-response relationships for each targeted pathway

  • Safety assessment with focus on potential off-target effects

  • Efficacy comparison with combination of individual antibodies

Building on existing knowledge of antibody gene transfer approaches, researchers could potentially use recombinant adeno-associated virus (rAAV) vectors encoding the genes for bispecific antibodies. Studies have demonstrated that rAAV-mediated antibody gene transfer to muscle results in sustained antibody production and secretion into circulation, with antibody levels typically between 4-5 μg/ml at 5 months post-injection . This approach could be adapted for bispecific anti-SeP antibodies to achieve long-term expression.

The development of such advanced antibody formats would represent a significant progression from current monoclonal antibody approaches and could potentially offer enhanced therapeutic benefits for metabolic disorders where multiple pathways contribute to disease pathology.